There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX – Research Report), Bioxcel Therapeutics (BTAI – Research Report) and Valneva (VALN – Research Report) with bullish sentiments.
Travere Therapeutics (TVTX)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Travere Therapeutics today and set a price target of $40.00. The company’s shares closed last Friday at $17.82.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 21.4% and a 43.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals.
Currently, the analyst consensus on Travere Therapeutics is a Strong Buy with an average price target of $36.63, implying a 76.9% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $52.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Bioxcel Therapeutics (BTAI)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics today and set a price target of $79.00. The company’s shares closed last Friday at $32.34, close to its 52-week high of $32.96.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -23.3% and a 27.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, MoonLake Immunotherapeutics, and Aquestive Therapeutics.
Bioxcel Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $48.20, implying a 48.0% upside from current levels. In a report issued on February 13, Bank of America Securities also maintained a Buy rating on the stock with a $46.00 price target.
Valneva (VALN)
H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva today and set a price target of $25.00. The company’s shares closed last Friday at $12.69, close to its 52-week low of $9.77.
According to TipRanks.com, White ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.0% and a 31.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Aeglea Biotherapeutics.
Valneva has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TVTX: